1. Home
  2. REFR vs CTSO Comparison

REFR vs CTSO Comparison

Compare REFR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Research Frontiers Incorporated

REFR

Research Frontiers Incorporated

HOLD

Current Price

$1.00

Market Cap

33.6M

Sector

Miscellaneous

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.79

Market Cap

45.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REFR
CTSO
Founded
1965
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Medical/Dental Instruments
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.6M
45.7M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
REFR
CTSO
Price
$1.00
$0.79
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
36.0K
62.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
33.33
N/A
EPS
N/A
N/A
Revenue
$1,488,642.00
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
N/A
$8.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.53
52 Week Low
$0.93
$0.60
52 Week High
$2.70
$1.39

Technical Indicators

Market Signals
Indicator
REFR
CTSO
Relative Strength Index (RSI) 36.50 71.21
Support Level $0.98 $0.62
Resistance Level $1.28 $0.85
Average True Range (ATR) 0.08 0.04
MACD 0.01 0.02
Stochastic Oscillator 12.39 84.73

Price Performance

Historical Comparison
REFR
CTSO

About REFR Research Frontiers Incorporated

Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: